Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT00493376
Other study ID # TPZ Targeting Cervix Study
Secondary ID
Status Terminated
Phase N/A
First received June 26, 2007
Last updated February 1, 2012
Start date August 2007

Study information

Verified date February 2012
Source British Columbia Cancer Agency
Contact n/a
Is FDA regulated No
Health authority Canada: Health Canada
Study type Observational

Clinical Trial Summary

The purpose of this study is as follows:

- to determine whether tirapazamine damages cervical tumour DNA immediately after its administration

- to determine the blood flow and oxygen level of cervical tumour before and after treatment with tirapazamine


Description:

Patients with locally advanced cervical cancer can have a poor clinical outcome with standard cisplatin and pelvic radiation therapy. It is well established that pre-treatment tumor hypoxia is a significant prognostic factor in tumors and may be one of the most important and modifiable mechanisms of radiation resistance in this group of tumours. Significant levels of hypoxia are not present in all locally advanced cervical tumors. Hence measurement of the pretreatment tumour oxygenation status is imperative, and can be assessed using various means. Immunohistochemical staining of various intrinsic hypoxia markers to include Ca9, Glut1, HIF-1 alpha on the pre-treatment tumours can be performed.

Tirapazamine, a bio-reductively activated hypoxic cell selective anti-tumour agent, has been found to act synergistically with cisplatinum, resulting in a significantly higher cell kill than expected based on additive action. We proposed to measure the cell killing effect of tirapazamine with the following tests:

- Comet assay: Tirapazamine causes DNA damage that can predict for cell killing by measuring DNA damage in cells from tumor biopsies using the alkaline comet assay.

- Measurement of phosphorylation of histone gamma H2AX: It has been explored as a measure of radiosensitivity in response to clinically relevant doses of radiation. The histone gamma H2AX phosphorylation can be used to detect tirapazamine induced DNA double-strand breaks and collapsed replication forks.

There is some evidence that the drug delivery may be impaired and in fact the drug may not actually be reaching all of the hypoxic tumour cells. A recent study has shown that, in an experimental setting, tirapazamine causes a decrease in vascular perfusion which can be measured with contrast enhanced MRI. We propose to assess if this mechanism is operative in human tumours.

Clinical studies have demonstrated that tumour vascular can increase during the course of radiation therapy, consistent with re-oxygenation and that this is suggestive of a better outcome. Tumours that become less hypoxic during the course of therapy have an increased likelihood of response to the given treatment. However, response to tirapazamine may be reduced. In order to assess both the vascular change that may occur directly because of tirapazamine infusion, as well as any increase in tumour vascularity and perhaps increase in tumour oxygenation during the course of therapy, we plan to assess these tumours during the course of therapy. Assessment of tumour perfusion and vessel permeability after 10 radiation treatments (on day 12) of chemo-radiation therapy will be performed via T1 weighted dynamic contrast enhanced MRI (DCMRI).

We hypothesize that:

1. Tirapazamine (a hypoxic cell cytotoxin and radiosensitizer) will result in increased DNA damage and a better clinical outcome if:

1. the pre-treatment tumor demonstrates significant hypoxia

2. tirapazamine treatment results in increased DNA damage

2. tirapazamine acts, in part, by changing vascular perfusion in the tumour and that these changes can be measured with dynamic contrast enhanced MRI.


Recruitment information / eligibility

Status Terminated
Enrollment 1
Est. completion date
Est. primary completion date
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Histologically confirmed clinically visible invasive carcinoma of the cervix, either squamous cell, adenocarcinoma or a variant of these

- Patients must be enrolled in NCIC CXC.1 (phase 3 study assessing the addition of tirapazamine) and randomized to the tirapazamine arm

- No known bleeding disorder

- Willing to undergo a clinical exam to obtain tissue biopsy for hypoxia marker analysis and DNA damage assessments

Exclusion Criteria:

- Inability to give informed consent

- Criteria below for contrast MRI only :

1. Chronic renal disease currently on dialysis

2. Renal insufficiency defined as a Glomerular Filtration Rate (GFR) =15cc/min , serum Cr >130, or a BUN>7 measured

3. Current pacemaker, tens neuro-stimulator, implanted drug infusion devices, any metal implants, foreign metals objects in eyes, aneurysm clips

Study Design

Observational Model: Cohort, Time Perspective: Prospective


Related Conditions & MeSH terms


Intervention

Procedure:
Cervical tissue biopsy analysis: Comet assay
Cervical tissue biopsy analysis: Comet assay
Biopsy: Measurement of histone gamma H2AX phosphorylation
Biopsy: Measurement of histone gamma H2AX phosphorylation
Biopsy: Immunohistochemistry: Ca9, Glut1, HIF-1 alpha
Biopsy: Immunohistochemistry: Ca9, Glut1, HIF-1 alpha
Measurement of vascular perfusion: contrast enhanced MRI
contrast enhanced MRI

Locations

Country Name City State
Canada British Columbia Cancer Agency, Vancouver Centre Vancouver British Columbia

Sponsors (2)

Lead Sponsor Collaborator
British Columbia Cancer Agency Canadian Institutes of Health Research (CIHR)

Country where clinical trial is conducted

Canada, 

See also
  Status Clinical Trial Phase
Recruiting NCT04067882 - Validation of the Genetic Signature 354849 as a Prognostic Method
Completed NCT00329589 - A Trial Using Velcade Plus Chemoradiation for Central Nervous System, Head and Neck, and Cervical Cancer Patients Phase 1
Recruiting NCT05743517 - Physical Activity Intervention Among Older Women With Gynecologic Cancers (Fit4Treatment) N/A
Completed NCT05234112 - Prevention and Screening Towards Elimination of Cervical Cancer N/A
Completed NCT04258553 - Thiol Disulfide Balance in Cervix Cancer
Completed NCT03956498 - Impact of a Sexological Follow-up on the Sexual Function in Patients With Cervix or Vaginal Cancer Treated by Radiotherapy and Brachytherapy N/A
Active, not recruiting NCT04357873 - Efficacy of Immunotherapy Plus a Drug in Patients With Progressive Advanced Mucosal Cancer of Different Locations Phase 2
Completed NCT00509444 - Cancer Prevention and Treatment Among African American Older Adults: Treatment Trial Phase 3
Completed NCT00379743 - Partnership for Healthy Seniors N/A
Recruiting NCT06022029 - A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas. Phase 1
Recruiting NCT06116019 - Online Adaptive Radiotherapy Using a Novel Linear Accelerator (ETHOS)
Completed NCT04072913 - Matrix Metalloproteinases and Human Papillomavirus in Dysplasias and Cancers of the Cervix N/A
Active, not recruiting NCT06452004 - Validation of Artificial Intelligence as Decision Support System in VIA (PRESCRIP-TEC) N/A
Recruiting NCT04651127 - Anti-PD-1 Antibody Combined With Histone Deacetylase Inhibitor in Patients With Advanced Cervical Cancer Phase 1/Phase 2
Recruiting NCT06010875 - A Clinical Research About CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Solid Tumors Phase 1
Completed NCT02552121 - Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors Phase 1/Phase 2
Completed NCT02001623 - Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors Phase 1/Phase 2
Completed NCT02997553 - Fluorescence for Sentinel Lymph Node Identification in Cancer Surgery Phase 3
Terminated NCT02233387 - PET CT With HX4 in Cervix Cancer Phase 2
Completed NCT01766284 - Study of the Diagnostic Efficacy of "Real Time" Niris 1300e Optical Coherence Tomography (OCT) Imaging System in the Management of Pre-invasive and Invasive Neoplasia of the Uterine Cervix N/A